Global methylation and promoter‑specific methylation of the P16, SOCS‑1, E‑cadherin, P73 and SHP‑1 genes and their expression in patients with multiple myeloma during active disease and remission

Martínez‑Baños,Déborah; Sánchez‑Hernández,Beatríz; Jiménez,Guadalupe; Barrera‑Lumbreras,Georgina; Barrales‑Benítez,Olga

doi:10.3892/etm.2017.4274

Global methylation and promoter‑specific methylation of the P16, SOCS‑1, E‑cadherin, P73 and SHP‑1 genes and their expression in patients with multiple myeloma during active disease and remission

Authors:
- Déborah Martínez‑Baños
- Beatríz Sánchez‑Hernández
- Guadalupe Jiménez
- Georgina Barrera‑Lumbreras
- Olga Barrales‑Benítez
View Affiliations

Affiliations: Department of Hematology and Oncology, National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Tlalpan 14080, Mexico, Department of Genetics, National Institute of Medical Science and Nutrition Salvador Zubiran, Mexico City, Tlalpan 14080, Mexico
Published online on: March 28, 2017 https://doi.org/10.3892/etm.2017.4274
Pages: 2442-2450

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor suppressor gene promoter CpG island methylation is a well-recognized mechanism in cancer pathogenesis, but its role in multiple myeloma (MM) is controversial. The present study investigated the methylation status and expression of P16, suppressor of cytokine signaling 1 (SOCS‑1), P73, E‑cadherin and Src homology region 2 domain‑containing phosphatase 1 (SHP‑1), as well as global methylation in patients with MM during active disease and remission. Bone marrow samples were obtained from 43 patients at the Multiple Myeloma Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (Mexico City, Mexico) during active disease and remission. Methylation‑specific polymerase chain reaction and ELISA were performed on bisulfite‑treated or untreated DNA to determine promoter‑specific or genomic methylation, respectively. Gene expression was measured using reverse‑transcription polymerase chain reaction. The results indicated that SOCS‑1 methylation occurred more frequently during active disease than remission [29 vs. 3.2% (P=0.021)] and was associated with more advanced forms of the disease [international staging system (ISS) 3, 16.67% vs. ISS 1, 8.3% (P=0.037)]. SHP‑1 methylation during active disease was associated with a lower probability of survival at 39‑month follow up (median), 52.5 vs. 87.5% (P=0.025). The percentage of methylation was associated with active disease at remission, but this was not significant. Global hypomethylation at remission was a negative predictor factor for overall survival (OS). The results indicated that methylated P16, SOCS‑1 and SHP‑1 were associated with clinical variables of poor prognosis in MM, likewise the persistence of global hypomethylation at remission. The negative impact on OS of global hypomethylation at remission must be confirmed in a larger sample. Future studies are necessary to investigate whether patients with global hypermethylation at remission should receive more aggressive treatments to improve their OS.

View Figures

View References

1	Kyle RA and Rajkumar SV: Treatment of multiple myeloma: A comprehensive review. Clin Lymphoma Myeloma. 9:278–288. 2009. View Article : Google Scholar : PubMed/NCBI
2	Sonneveld P and Broijl A: Treatment of relapsed and refractory multiple myeloma. Haematologica. 101:396–406. 2016. View Article : Google Scholar : PubMed/NCBI
3	Gonzalez-Paz N, Chng WJ, McClure RF, Blood E, Oken MM, Van Ness B, James CD, Kurtin PJ, Henderson K, Ahmann GJ, et al: Tumor suppressor p16 methylation in multiple myeloma: Biological and clinical implications. Blood. 109:1228–1232. 2007. View Article : Google Scholar : PubMed/NCBI
4	Mateos MV, García-Sanz R, López-Pérez R, Moro MJ, Ocio E, Hernández J, Megido M, Caballero MD, Fernández-Calvo J, Bárez A, et al: Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol. 118:1034–1040. 2002. View Article : Google Scholar : PubMed/NCBI
5	Reik W, Dean W and Walter J: Epigenetic reprogramming in mammalian development. Science. 293:1089–1093. 2001. View Article : Google Scholar : PubMed/NCBI
6	Baylin SB, Esteller M, Rountree MR, Bachman KE, Schuebel K and Herman JG: Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet. 10:687–692. 2001. View Article : Google Scholar : PubMed/NCBI
7	Jones PL and Wolffe AP: Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol. 9:339–347. 1999. View Article : Google Scholar : PubMed/NCBI
8	Fatemi M, Pao MM, Jeong S, Gal-Yam EN, Egger G, Weisenberger DJ and Jones PA: Footprinting of mammalian promoters: Use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level. Nucleic Acids Res. 33:e1762005. View Article : Google Scholar : PubMed/NCBI
9	Ahuja N and Issa JP: Aging, methylation and cancer. Histol Histopathol. 15:835–842. 2000.PubMed/NCBI
10	Jones PA and Baylin SB: The epigenomics of cancer. Cell. 128:683–692. 2007. View Article : Google Scholar : PubMed/NCBI
11	Berdasco M and Esteller M: Aberrant epigenetic landscape in cancer: How cellular identity goes awry. Dev Cell. 19:698–711. 2010. View Article : Google Scholar : PubMed/NCBI
12	Asmar F, Punj V, Christensen J, Pedersen MT, Pedersen A, Nielsen AB, Hother C, Ralfkiaer U, Brown P, Ralfkiaer E, et al: Genome-wide profiling identifies a DNA methylation signature that associates with TET2 mutations in diffuse large B-cell lymphoma. Haematologica. 98:1912–1920. 2013. View Article : Google Scholar : PubMed/NCBI
13	Sandoval J, Mendez-Gonzalez J, Nadal E, Chen G, Carmona FJ, Sayols S, Moran S, Heyn H, Vizoso M, Gomez A, et al: A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol. 31:4140–4147. 2013. View Article : Google Scholar : PubMed/NCBI
14	Esteller M: Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 8:286–298. 2007. View Article : Google Scholar : PubMed/NCBI
15	Portela A and Esteller M: Epigenetic modifications and human disease. Nat Biotechnol. 28:1057–1068. 2010. View Article : Google Scholar : PubMed/NCBI
16	Shen L, Kondo Y, Guo Y, Zhang J, Zhang L, Ahmed S, Shu J, Chen X, Waterland RA and Issa JP: Genome-wide profiling of DNA methylation reveals a class of normally methylated CpG island promoters. PLoS Genet. 3:2023–2036. 2007. View Article : Google Scholar : PubMed/NCBI
17	Issa JP and Kantarjian HM: Targeting DNA methylation. Clin Cancer Res. 15:3938–3946. 2009. View Article : Google Scholar : PubMed/NCBI
18	Lee ES, Issa JP, Roberts DB, Williams MD, Weber RS, Kies MS and El-Naggar AK: Quantitative promoter hypermethylation analysis of cancer-related genes in salivary gland carcinomas: Comparison with methylation-specific PCR technique and clinical significance. Clin Cancer Res. 14:2664–2672. 2008. View Article : Google Scholar : PubMed/NCBI
19	Li H, Chiappinelli KB, Guzzetta AA, Easwaran H, Yen RW, Vatapalli R, Topper MJ, Luo J, Connolly RM, Azad NS, et al: Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers. Oncotarget. 5:587–598. 2014. View Article : Google Scholar : PubMed/NCBI
20	González M, Mateos MV, García-Sanz R, Balanzategui A, López-Pérez R, Chillón MC, González D, Alaejos I and Miguel San JF: De novo methylation of tumor suppressor gene p16/INK4a is a frequent finding in multiple myeloma patients at diagnosis. Leukemia. 14:183–187. 2000. View Article : Google Scholar : PubMed/NCBI
21	Krämer A, Schultheis B, Bergmann J, Willer A, Hegenbart U, Ho AD, Goldschmidt H and Hehlmann R: Alterations of the cyclin D1/pRb/p16(INK4A) pathway in multiple myeloma. Leukemia. 16:1844–1851. 2002. View Article : Google Scholar : PubMed/NCBI
22	Galm O, Yoshikawa H, Esteller M, Osieka R and Herman JG: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood. 101:2784–2788. 2003. View Article : Google Scholar : PubMed/NCBI
23	Chim CS, Liang R, Leung MH, Yip SF and Kwong YL: Aberrant gene promoter methylation marking disease progression in multiple myeloma. Leukemia. 20:1190–1192. 2006. View Article : Google Scholar : PubMed/NCBI
24	Amatori S, Bagaloni I, Donati B and Fanelli M: DNA demethylating antineoplastic strategies: A comparative point of view. Genes Cancer. 1:197–209. 2010. View Article : Google Scholar : PubMed/NCBI
25	Flotho C, Claus R, Batz C, Schneider M, Sandrock I, Ihde S, Plass C, Niemeyer CM and Lübbert M: The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia. 23:1019–1028. 2009. View Article : Google Scholar : PubMed/NCBI
26	Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al: International uniform response criteria for multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
27	Draube A, Pfister R, Vockerodt M, Schuster S, Kube D, Diehl V and Tesch H: Immunomagnetic enrichment of CD138 positive cells from weakly infiltrated myeloma patients samples enables the determination of the tumor clone specific IgH rearrangement. Ann Hematol. 80:83–89. 2001. View Article : Google Scholar : PubMed/NCBI
28	Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB: Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA. 93:9821–9826. 1996. View Article : Google Scholar : PubMed/NCBI
29	Miguel San J, Schlag R, Khuageva N, Dimopoulos M, Schpilberg O, Kropff M, Spicka I, Petrucci M, Palumbo A, Samoilova O, et al: Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 359:906–917. 2008. View Article : Google Scholar : PubMed/NCBI
30	Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Eng J Med. 352:2487–2498. 2005. View Article : Google Scholar
31	Greipp PR, Miguel San J, Durie BG, Crowley JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, et al: International staging system for multiple myeloma. J Clin Oncol. 23:3412–3420. 2005. View Article : Google Scholar : PubMed/NCBI
32	Guillerm G, Depil S, Wolowiec D and Quesnel B: Different prognostic values of p15(INK4b) and p16(INK4a) gene methylations in multiple myeloma. Haematologica. 88:476–478. 2003.PubMed/NCBI
33	Galm O, Wilop S, Reichelt J, Jost E, Gehbauer G, Herman JG and Osieka R: DNA methylation changes in multiple myeloma. Leukemia. 18:1687–1692. 2004. View Article : Google Scholar : PubMed/NCBI
34	Deng G, Chen A, Hong J, Chae HS and Kim YS: Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res. 59:2029–2033. 1999.PubMed/NCBI
35	Deng G, Chen A, Pong E and Kim YS: Methylation in hMLH1 promoter interferes with its binding to transcription factor CBF and inhibits gene expression. Oncogene. 20:7120–7127. 2001. View Article : Google Scholar : PubMed/NCBI
36	Depil S, Saudemont A and Quesnel B: SOCS-1 gene methylation is frequent but does not appear to have prognostic value in patients with multiple myeloma. Leukemia. 17:1678–1679. 2003. View Article : Google Scholar : PubMed/NCBI
37	Kyle RA and Rajkumar SV: Multiple myeloma. N Engl J Med. 351:1860–1873. 2004. View Article : Google Scholar : PubMed/NCBI
38	Roman-Gomez J, Jimenez-Velasco A, Castillejo JA, Cervantes F, Barrios M, Colomer D, Heininger A and Torres A: The suppressor of cytokine signaling-1 is constitutively expressed in chronic myeloid leukemia and correlates with poor cytogenetic response to interferon-alpha. Haematologica. 89:42–48. 2004.PubMed/NCBI
39	Li Z, Metze D, Nashan D, Müller-Tidow C, Serve HL, Poremba C, Luger TA and Böhm M: Expression of SOCS-1, suppressor of cytokine signalling-1, in human melanoma. J Invest Dermatol. 123:737–745. 2004. View Article : Google Scholar : PubMed/NCBI
40	Qu Y, Dang S and Hou P: Gene methylation in gastric cancer. Clin Chim Acta. 424:53–65. 2013. View Article : Google Scholar : PubMed/NCBI
41	Mateos MV, Garcia-Sanz R, López-Pérez R, Balanzategui A, González MI, Fernández-Calvo J, Moro MJ, Hernández J, Caballero MD, González M and Miguel San JF: p16/INK4a gene inactivation by hypermethylation is associated with aggressive variants of monoclonal gammopathies. Hematol J. 2:146–149. 2001. View Article : Google Scholar : PubMed/NCBI
42	Guillerm G, Depil S, Wolowiec D and Quesnel B: Different prognostic values of p15 (INK4b) and p16 (INK4a) gene methylations in multiple myeloma. Haematologica. 88:476–478. 2003.PubMed/NCBI
43	Ribas C, Colleoni GW, Felix RS, Silva Regis MR, Caballero OL, Brait M and Bordin JO: p16 gene methylation lacks correlation with angiogenesis and prognosis in multiple myeloma. Cancer Lett. 26:247–254. 2005. View Article : Google Scholar
44	Chim CS, Fung TK, Cheung WC, Liang R and Kwong YL: SOCS1 and SHP1 hypermethylation in multiple myeloma: Implications for epigenetic activation of the Jak/STAT pathway. Blood. 103:46302004. View Article : Google Scholar : PubMed/NCBI
45	Esposito N, Colavita I, Quintarelli C, Rodeo A, AL Peluso Luciano L, Picardi M, Vecchio L, Buonomo T and Hughes T: SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia.
46	Valentino L and Pierre J: JAK/STAT signal transduction: Regulators and implications in hematological malignancies. Biochem Pharmacol. 71:713–721. 2006. View Article : Google Scholar : PubMed/NCBI
47	Zhang HF and Lai R: STAT3 in cancer-friend or Foe? Cancers (Basel). 6:1408–1440. 2004. View Article : Google Scholar
48	de Fernández Larrea C, Martín-Antonio B, Cibeira MT, Navarro A, Tovar N, Díaz T, Rosiñol L, Monzó M, Urbano-Ispizua A and Bladé J: Impact of global and gene-specific DNA methylation pattern in relapsed multiple myeloma patients treated with bortezomib. Leuk Res. 37:641–646. 2013. View Article : Google Scholar : PubMed/NCBI
49	Homedes N and Ugalde A: Availability and affordability of new medicines in Latin American countries where pivotal clinical trials were conducted. Bull World Health Organ. 93:674–683. 2015. View Article : Google Scholar : PubMed/NCBI
50	Pichon-Riviere A, Garay OU, Augustovski F, Vallejos C, Huayanay L, Mdel Bueno P, Rodriguez A, de Andrade CJ, Buendía JA and Drummond M: Implications of global pricing policies on access to innovative drugs: The case of trastuzumab in seven Latin American countries. Int J Technol Assess Health Care. 31:2–11. 2015. View Article : Google Scholar : PubMed/NCBI
51	Goss PE, Lee BL, Badovinac-Crnjevic T, Strasser-Weippl K, Chavarri-Guerra Y, St Louis J, Villarreal-Garza C, Unger-Saldaña K, Ferreyra M, Debiasi M, et al: Planning cancer control in Latin America and the Caribbean. Lancet Oncol. 14:391–436. 2013. View Article : Google Scholar : PubMed/NCBI
52	Amador-Medina LF, Lacayo-Leñero D, Crespo-Solís E, Aguayo Á and Martínez-Baños D: Thalidomide and dexamethasone induction therapy until best response in recently diagnosed patients with multiple myeloma: Results from a pilot study. Rev Invest Clin. 67:304–312. 2015.PubMed/NCBI
53	Knaul FM, González-Pier E, Gómez-Dantés O, García-Junco D, Arreola-Ornelas H, Barraza-Lloréns M, Sandoval R, Caballero F, Hernández-Avila M, Juan M, et al: The quest for universal health coverage: Achieving social protection for all in Mexico. Lancet. 380:1259–1279. 2012. View Article : Google Scholar : PubMed/NCBI